The Inhalation CDMO Market Size was valued at USD 7.9 Bn in 2023 and is predicted to reach USD 11.8 Bn by 2031 at a 5.2% CAGR during the forecast period for 2024-2031.
Inhalation CDMO refers to the organization that is responsible for the development and manufacturing of inhalation contracts. For the research and production of inhalation medicinal products, these specialized service providers offer solutions that cover the entire continuum. One of the main factors fueling the growth of the inhalation CDMO market is the increasing number of respiratory disorders globally. Air pollution, an aging population, and increased urbanization are contributing to the alarming increase in chronic obstructive pulmonary disease, cystic fibrosis, and asthma cases.
The inhalation CDMO industry is leading the way in technological innovation, improving inhalation medicines' safety, effectiveness, and patient experience by utilizing new ideas in aerosol science, device design, and manufacturing processes. Furthermore, the inhalation CDMO market has a lot of potential due to factors such the growing need for novel inhalation medicines, improvements in drug delivery technologies, and the trend of pharmaceutical companies outsourcing more and more to simplify production and development.
However, the market growth is hampered due to complex formulation procedures, high development and manufacturing expenses, and strict regulatory restrictions. Smaller businesses find it challenging to break into a market due to the high operational costs caused by the requirement for specialized equipment and experience. The COVID-19 pandemic has sped up the inhalation CDMO market because of higher demand for respiratory treatments, shorter lead times for drug development, and a greater focus on advanced drug delivery methods. This has led to more investment and new ideas in the inhalation CDMO market. Furthermore, rising collaborations between pharmaceutical firms and CDMO to address critical healthcare demands, faster drug approval processes, and heightened attention to respiratory health all contributed to the market's meteoric rise.
The global inhalation CDMO market is segmented based on service, product, company size and scale of operation. Based on service, the market is segmented into formulation development, device development and manufacturing, clinical manufacturing, scale-up and tech transfer, quality control and quality assurance, technology and innovation, regulatory assistance, and analytical services. By product, the market is segmented into API and inhalation platforms. The market is segmented by company size into large, medium, and small. By scale of operation, the market is segmented into preclinical, clinical, and commercial.
The formulation development segment is expected to hold a major global market share in 2023 because new and improved inhalation treatments are in high demand. A lot of investment and effort has gone into developing effective drug delivery methods, assuring medication stability, and meeting demanding regulatory standards. To achieve these goals, advanced formulation processes are essential, which in turn drives their widespread use and substantial market share.
The inhalation platform segment in the inhalation CDMO market is growing because there is a growing need for focused and effective drug delivery systems for respiratory disorders. This market is experiencing rapid innovation due to technological advancements like dry powder inhalers and metered-dose inhalers. The demand for safe and effective inhalation treatments is another factor driving the expansion of inhalation platforms.
The North American inhalation CDMO market is expected to register the highest market share in revenue in the near future. This is because there is a robust healthcare system, many people suffer from respiratory illnesses, a lot of money spent on research and development, and a powerful pharmaceutical sector. Major inhalation businesses are located in the region, which helps fuel the expansion of the market. In addition, Asia Pacific is projected to grow rapidly in the global inhalation CDMO market as a result of its burgeoning pharmaceutical industry, skyrocketing healthcare costs, increasing number of cases of respiratory disorders, and skyrocketing spending in R&D. Additionally, market expansion in the region is being propelled by a big patient population and supportive government efforts.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 7.95 Bn |
|
Revenue Forecast In 2031 |
USD 11.85 Bn |
|
Growth Rate CAGR |
CAGR of 5.2% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Service, By Application, By Company Size, By Scale of Operation |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Recipharm AB, AptarGroup Inc., Hovione, Vectura Group Ltd, Nemera, Kindeva, H&T Presspart, Sanner GmbH, Stevanato Group, Medspray, ICONOVO AB, Lonza, Gerresheimer AG, Catalent, Thermo Fisher Scientific Inc., Lubrizol Life Science, Enteris BioPharma, Cambrex Corporation, INKE, Piramal Pharma Limited, Lupin, and Others. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Inhalation CDMO Market Snapshot
Chapter 4. Global Inhalation CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Product Estimates & Trend Analysis
5.1. By Product & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Product:
5.2.1. API
5.2.1.1. API Substrate
5.2.1.2. Large Molecule
5.2.1.3. Small Molecule
5.2.2. Inhalation Platform
5.2.2.1. Dry Powder Inhaler (DPIs)
5.2.2.2. Metered Dose Inhaler (MDIs)
5.2.2.3. Soft Mist Inhaler
Chapter 6. Market Segmentation 2: By Service Estimates & Trend Analysis
6.1. By Service & Market Share, 2023 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Service:
6.2.1. Formulation Development
6.2.2. Device Development and Manufacturing
6.2.3. Clinical Manufacturing
6.2.4. Scale-up and Tech Transfer
6.2.5. Quality Control and Quality Assurance
6.2.6. Technology and Innovation
6.2.7. Regulatory Assistance
6.2.8. Analytical Services
Chapter 7. Market Segmentation 3: By Company Size Estimates & Trend Analysis
7.1. By Company Size & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Company Size:
7.2.1. Large
7.2.2. Medium
7.2.3. Small
Chapter 8. Market Segmentation 4: by Scale of Operation Estimates & Trend Analysis
8.1. by Scale of Operation & Market Share, 2023 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Scale of Operation:
8.2.1. Preclinical
8.2.2. Clinical
8.2.3. Commercial
Chapter 9. Inhalation CDMO Market Segmentation 4: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
9.1.2. North America Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2024-2031
9.1.3. North America Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service, 2024-2031
9.1.4. North America Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Company Size, 2024-2031
9.1.5. North America Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.2. Europe
9.2.1. Europe Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
9.2.2. Europe Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2024-2031
9.2.3. Europe Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service, 2024-2031
9.2.4. Europe Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Company Size, 2024-2031
9.2.5. Europe Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
9.3.2. Asia Pacific Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2024-2031
9.3.3. Asia Pacific Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service, 2024-2031
9.3.4. Asia Pacific Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Company Size, 2024-2031
9.3.5. Asia Pacific Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.4. Latin America
9.4.1. Asia Pacific Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
9.4.2. Asia Pacific Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2024-2031
9.4.3. Latin America Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service, 2024-2031
9.4.4. Latin America Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Company Size, 2024-2031
9.4.5. Latin America Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
9.5.2. Middle East & Africa Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2024-2031
9.5.3. Middle East & Africa Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service, 2024-2031
9.5.4. Middle East & Africa Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by Company Size, 2024-2031
9.5.5. Middle East & Africa Inhalation CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Recipharm AB
10.2.2. AptarGroup Inc.
10.2.3. Hovione
10.2.4. Vectura Group Ltd
10.2.5. Nemera
10.2.6. Kindeva
10.2.7. H&T Presspart
10.2.8. Sanner GmbH
10.2.9. Stevanato Group
10.2.10. Medspray
10.2.11. ICONOVO AB
10.2.12. Lonza
10.2.13. Gerresheimer AG
10.2.14. Catalent
10.2.15. Thermo Fisher Scientific Inc.
10.2.16. Lubrizol Life Science
10.2.17. Enteris BioPharma
10.2.18. Cambrex Corporation
10.2.19. INKE
10.2.20. Piramal Pharma Limited
10.2.21. Lupin
10.2.22. Other Prominent Players
Inhalation CDMO Market- By Service
Inhalation CDMO Market- By Application
Inhalation CDMO Market- By Company Size
Inhalation CDMO Market- By Scale of Operation
Inhalation CDMO Market- By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of the Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
